92 related articles for article (PubMed ID: 22533368)
1. Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Gerecitano J; Gounder S; Teruya-Feldstein J; Arcila M; Ogilvie S; Gonzalez C; Lin D; Zheng J; Zhang Z; McDonald A; Mulligan G; O'Connor OA
Br J Haematol; 2012 Jul; 158(2):290-292. PubMed ID: 22533368
[No Abstract] [Full Text] [Related]
2. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
[TBL] [Abstract][Full Text] [Related]
3. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Moosmann P; Heizmann M; Kotrubczik N; Wernli M; Bargetzi M
Leuk Lymphoma; 2010 Jan; 51(1):149-52. PubMed ID: 19860608
[No Abstract] [Full Text] [Related]
4. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Younes A; Pro B; Fayad L
Blood; 2006 Feb; 107(4):1731-2. PubMed ID: 16461762
[No Abstract] [Full Text] [Related]
5. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Goy A; Bernstein SH; McDonald A; Pickard MD; Shi H; Fleming MD; Bryant B; Trepicchio W; Fisher RI; Boral AL; Mulligan G
Leuk Lymphoma; 2010 Jul; 51(7):1269-77. PubMed ID: 20572799
[TBL] [Abstract][Full Text] [Related]
6. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
8. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
10. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
11. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
[TBL] [Abstract][Full Text] [Related]
13. Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?
Paydas S
Leuk Lymphoma; 2006 Nov; 47(11):2412-3. PubMed ID: 17107919
[No Abstract] [Full Text] [Related]
14. Review. Clinical pharmacokinetics of bortezomib.
Levêque D; Carvalho MC; Maloisel F
In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
[TBL] [Abstract][Full Text] [Related]
15. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
16. Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
O'Connor O; Wright J; Moskowitz CH; Muzzy J; MacGregor-Cortelli B; Hamlin P; Straus D; Trehu E; Schenkein DP; Zelenetz AD
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S21-2. PubMed ID: 19791425
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.
Mazepa MA; Raval JS; Moll S; Ma A; Park YA
Br J Haematol; 2014 Mar; 164(6):900-2. PubMed ID: 24345005
[No Abstract] [Full Text] [Related]
18. Proteasome inhibitors in non-Hodgkin's lymphoma.
Zelenetz A
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S34-6. PubMed ID: 16280110
[No Abstract] [Full Text] [Related]
19. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
20. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Gerecitano J; Goy A; Wright J; MacGregor-Cortelli B; Neylon E; Gonen M; Esseltine D; Boral A; Schenkein D; Busam K; Teruya-Feldstein J; Sachs D; O'Connor OA
Br J Haematol; 2006 Aug; 134(4):391-8. PubMed ID: 16882131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
